Canada Gazette, Part I, Volume 159, Number 49: GOVERNMENT NOTICES

December 6, 2025

DEPARTMENT OF THE ENVIRONMENT

CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999

Notice amending the Notice with respect to reporting of greenhouse gases (GHGs) for 2024 and 2025

Notice is hereby given, pursuant to subsection 46(1) of the Canadian Environmental Protection Act, 1999, that the Notice with respect to reporting of greenhouse gases (GHGs) for 2024 and 2025, published on December 9, 2023, in the Canada Gazette, Part I, is amended as set out in the schedule to this notice.

Enquiries concerning this notice may be addressed to the following address:

Greenhouse Gas Reporting Program
Pollutant Inventories and Reporting Division
Environment and Climate Change Canada
Place Vincent Massey
351 Saint-Joseph Boulevard
Gatineau, Quebec
K1A 0H3
Telephone: 819‑938‑3258 or 1‑877‑877‑8375
Email: ges-ghg@ec.gc.ca

Jacqueline Gonçalves
Director General
Science Reporting and Assessment Directorate
On behalf of the Minister of the Environment

SCHEDULE

Amendments

1. The title of the Notice with respect to reporting of greenhouse gases (GHGs) for 2024 and 2025 is replaced by the following:

Notice with respect to reporting of greenhouse gases (GHGs) for 2024, 2025 and 2026

2. The first two paragraphs of the Notice with respect to reporting of greenhouse gases (GHGs) for 2024 and 2025 are replaced by the following:

Notice is hereby given, pursuant to subsection 46(1) of the Canadian Environmental Protection Act, 1999 (the Act), that, with respect to emissions of greenhouse gases (GHGs) identified in Schedule 1 to this notice and for the purpose of conducting research, creating an inventory of data, formulating objectives and codes of practice, issuing guidelines or assessing or reporting on the state of the environment, any person who operates a facility described in Schedule 3 to this notice during the 2024, 2025 or 2026 calendar year, and who possesses or who may reasonably be expected to have access to information described in Schedules 4 through 18 to this notice, shall provide the Minister of the Environment with this information for the relevant calendar year or years.

This notice applies to the calendar years 2024, 2025 and 2026. Information pertaining to the 2024 calendar year shall be provided no later than June 2, 2025. Information pertaining to the 2025 calendar year shall be provided no later than June 1, 2026. Information pertaining to the 2026 calendar year shall be provided no later than June 1, 2027.

3. The fifth paragraph of the Notice with respect to reporting of greenhouse gases (GHGs) for 2024 and 2025 is replaced by the following:

If a person who operates a facility with respect to which information was submitted for the 2023 calendar year in response to the Notice with respect to reporting of greenhouse gases (GHGs) for 2022 and 2023 determines that the facility does not meet the criteria set out in Schedule 3 of this notice for the 2024 calendar year, the person shall notify the Minister of the Environment that the facility does not meet those criteria no later than June 2, 2025. If a person who operates a facility with respect to which information is submitted for the 2024 calendar year in response to this notice determines that the facility does not meet any of the criteria set out in this notice for the 2025 calendar year, the person shall notify the Minister of the Environment that the facility does not meet these criteria no later than June 1, 2026. If a person who operates a facility with respect to which information is submitted for the 2025 calendar year in response to this notice determines that the facility does not meet any of the criteria set out in this notice for the 2026 calendar year, the person shall notify the Minister of the Environment that the facility does not meet these criteria no later than June 1, 2027.

4. Paragraph 1(a) of Schedule 3 of the Notice with respect to reporting of greenhouse gases (GHGs) for 2024 and 2025 is replaced by the following:

(a) a facility that emits 10 000 tonnes of carbon dioxide equivalent or more (the “reporting threshold”) of GHGs in the 2024 calendar year, the 2025 calendar year or the 2026 calendar year;

5. The portion of paragraph 1(b) of Schedule 3 of the Notice with respect to reporting of greenhouse gases (GHGs) for 2024 and 2025 before subparagraph (i) is replaced by the following:

(b) a facility that emits 10 000 tonnes of carbon dioxide equivalent or more (the “reporting threshold”) of GHGs in the 2024 calendar year, the 2025 calendar year or the 2026 calendar year and meets both of the criteria listed in subparagraphs (i) and (ii) below:

6. Paragraph 1(c) of Schedule 3 of the Notice with respect to reporting of greenhouse gases (GHGs) for 2024 and 2025 is replaced by the following:

(c) a facility engaged in CO₂ capture, CO₂ transport, CO₂ injection, CO₂ utilization or CO₂ storage in the 2024 calendar year, the 2025 calendar year or the 2026 calendar year.

7. The portion of section 2 of Schedule 3 of the Notice with respect to reporting of greenhouse gases (GHGs) for 2024 and 2025 before paragraph (a) is replaced by the following:

2. Any person who operates a facility described in this notice shall determine whether the facility meets or exceeds the reporting threshold referred to in paragraph 1(a) or (b) using the following equation and the steps described in paragraphs 2(a) to 2(c):

Total Emissions (in CO₂ eq.) = ∑₁ⁱ(E_CO2 × GWP_CO2) _i + ∑₁ⁱ(E_CH4 × GWP_CH4)_i + ∑₁ⁱ(E_N2O × GWP_N2O) _i + ∑₁ⁱ(E_HFC × GWP_HFC)_i + ∑₁ⁱ(E_PFC × GWP_PFC)_i + ∑₁ⁱ(E_SF6 × GWP_SF6)_i: Where:
E =: total emissions, from all activities occurring at the facility, of a particular GHG in calendar year 2024, 2025 or 2026, expressed in tonnes
GWP =: global warming potential of the particular GHG
i =: each emission source

EXPLANATORY NOTE

(This note is not part of the notice.)

The amendments are made to reflect that the reporting requirements applicable to calendar years 2024 and 2025 are also now applicable to the 2026 calendar year.

DEPARTMENT OF THE ENVIRONMENT DEPARTMENT OF HEALTH

CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999

Publication of the approach and results of investigations for 6 604 substances specified on the Domestic Substances List

Whereas Environment and Climate Change Canada and Health Canada developed a science approach document describing a scientific approach that was applied to 6 604 substances specified on the Domestic Substances List (DSL) in order to identify and prioritize substances that may be of human health or ecological concern based on indicators of hazard and potential for exposure in relation to their use in plastics;

And whereas the approach outlined in the science approach document was used to assist the Government of Canada in identifying priorities for assessment to be considered for inclusion on the plan described in section 73 of the Canadian Environmental Protection Act, 1999 (the Act),

Notice is hereby given that the approach outlined in the science approach document may be used for future chemical prioritization and planning of assessment activities under section 68 of the Act.

Public comment period — December 6, 2025, to February 4, 2026

Any person may, within 60 days after publication of this notice, file with the Minister of the Environment written comments on the scientific considerations presented in the science approach document. More information regarding the scientific considerations may be obtained from the Canada.ca (Chemical substances) website. The science approach document may also be consulted.

How to participate: All comments must cite the Canada Gazette, Part I, and the date of publication of this notice and be sent to the Substances Management Information Line, Department of the Environment, Gatineau, Quebec K1A 0H3,

by email to substances@ec.gc.ca; or
by using the online reporting system available through Environment and Climate Change Canada’s Single Window.

In accordance with section 313 of the Canadian Environmental Protection Act, 1999, any person who provides information in response to this notice may submit with the information a request that it be treated as confidential. The request must provide reasons as provided for under subsection 313(2) of the Act.

Jacqueline Gonçalves
Director General
Science Reporting and Assessment Directorate
On behalf of the Minister of the Environment

Greg Carreau
Director General
Safe Environments Directorate
On behalf of the Minister of Health

DEPARTMENT OF HEALTH

DEPARTMENT OF HEALTH ACT

Notice of annual increase of Health Canada’s Drug Master Files and Certificate of Pharmaceutical Product fees

Notice is hereby given that the Minister of Health, under the Ministerial Authority to Enter into Contract, updates the fees that are payable for the provision of Drug Master Files and Certificate of Pharmaceutical Product services by 2%, rounded up to the nearest dollar.

The current fees and the fees updated as of April 1, 2026, are listed below.

Any inquiries or comments about the updated fees can be directed to Rosslynn Miller-Lee, Director General, Business Facilitation and Modernization Directorate, Health Products and Food Branch, 613‑327‑0798 (telephone) or cro-brc@hc-sc.gc.ca (email).

Annual increase of Drug Master Files and Certificate of Pharmaceutical Prod+uct fees
Services	Fee as of April 1, 2025	Fee as of April 1, 2026
Certificate of Pharmaceutical Product (or a supplemental copy of a Certificate of Pharmaceutical Product)	$102	$105
New Master Files (file registration)	$1,407	$1,436
Drug Master Files — letter of access	$200	$204
Drug Master Files — update	$611	$624

DEPARTMENT OF HEALTH

FINANCIAL ADMINISTRATION ACT

Notice of annual adjustment of fees for dealer’s licences

Notice is hereby given, under section 19.2 of the Financial Administration Act, that in keeping with section 4 of the Fees in Respect of Dealer’s Licences Regulations, the fee for dealer’s licences: human drugs will increase by the annual 2% amount, rounded up to the nearest dollar. Under subsection 17(1) of the Service Fees Act (a fee is adjusted in each fiscal year — on the anniversary of a date that is selected by the responsible authority with respect to the fee before the first adjustment — by the percentage change over 12 months in the April All-items Consumer Price Index [CPI] for Canada, as published by Statistics Canada under the Statistics Act, for the previous fiscal year), the dealer’s licence: veterinary drugs (as per the Licensed Dealers for Controlled Drugs and Narcotics (Veterinary Use) Fees Regulations) will be adjusted by the CPI. Health Canada has chosen April 1 as the anniversary date. The CPI for this year is 1.7%.

The current fees and the fees updated as of April 1, 2026, are listed below.

Annual adjustment of fees for dealer’s licences
Type of licence	Fee as of April 1, 2025	Fee as of April 1, 2026
Dealer’s licence (human drugs)	$5,958	$6,078
Dealer’s licence (veterinary drugs)	$2,155.66	$2,192.31
Dealer’s licence (veterinary drugs, first year)	$1,077.84	$1,096.16

DEPARTMENT OF HEALTH

FOOD AND DRUGS ACT

Notice of annual adjustment of the Fees in Respect of Drugs and Medical Devices Order

Notice is hereby given, under subsection 30.61(1) of the Food and Drugs Act, that in keeping with section 4.1 of the 2020 Fees in Respect of Drugs and Medical Devices Order, every fee outlined in the Order is to be adjusted annually based on the Consumer Price Index (CPI), rounded up to the nearest dollar. The CPI is calculated based on the percentage change over 12 months in the April All-items CPI for Canada, as published by Statistics Canada under the Statistics Act, for the previous fiscal year. The CPI for this year is 1.7%.

Some fees in the Fees in Respect of Drugs and Medical Devices Order are currently being phased in over seven years.

The current fees and the fees updated as of April 1, 2026, are listed below.

Human Drug Submission Review

Part 2 — Drugs

Table 1: Fees for examination of a submission — drugs for human use (Schedule 1)
Section in the Fees in Respect of Drugs and Medical Devices Order	Submission class	Fee as of April 1, 2025	Fee as of April 1, 2026
Section 9	New active substance	$606,286	$616,593
	Clinical or non-clinical data and chemistry and manufacturing data	$313,944	$319,282
	Clinical or non-clinical data only	$125,533	$127,668
	Comparative studies	$70,750	$71,953
	Chemistry and manufacturing data only	$43,529	$44,269
	Clinical or non-clinical data only, in support of safety updates to the labelling	$22,977	$23,368
	Labelling only	$6,328	$6,436
	Labelling only (generic drugs)	$2,378	$2,419
	Administrative submission	$1,002	$1,020
	Disinfectant — full review	$13,186	$13,411
	Labelling only (disinfectants)	$2,964	$3,015
	Drug identification number application — labelling standard	$1,912	$1,945

Table 2: Fees for examination of a submission — drugs for veterinary use only (Schedule 2)
Section in the Fees in Respect of Drugs and Medical Devices Order	Type of submission	Component	Fee as of April 1, 2025	Fee as of April 1, 2026
Section 21	Application for drug identification number (DIN)	Information, other than that referred to in the item below, to support an application for a drug identification number, including the submission of labelling material for a second review, if required	$2,606	$2,946
		Published references or other data	$1,812	$2,047
		Documentation to support a change of manufacturer, a change to the name of a manufacturer or a change to the brand name of a drug	$906	$1,025
	Notification — veterinary health product	Information contained in a notification filed under subsection C.01.615(1) of the Food and Drug Regulations in respect of a veterinary health product	$578	$588
	New drug submissions (NDS)	Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in one animal species (in the case of an antiparasitic drug, several indications in one food animal species)	$57,787	$65,297
		Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species	$35,006	$39,557
		Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration and dosage form and two indications in one animal species	$84,038	$94,961
		Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species	$113,795	$128,589
		Comparative (pharmacodynamic, clinical or bioavailability) data to support an additional route of administration	$10,491	$11,855
		Comparative (pharmacodynamic, clinical or bioavailability) data to support each additional strength	$1,739	$1,964
		For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1 000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species	$78,793	$89,035
		For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1 000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species	$105,044	$118,700
		For food-producing animals, residue depletion studies to establish a withdrawal period for an additional dosage form, dosage or route of administration	$10,491	$11,855
		For food-producing animals (once an acceptable daily intake with a safety factor of 1 000 or less has been established), metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in an additional species	$52,506	$59,332
		Chemistry and manufacturing data for a non-compendial medicinal ingredient of a drug	$17,505	$19,780
		Chemistry and manufacturing data to support one strength of a single dosage form	$17,505	$19,780
		Chemistry and manufacturing data to support an additional strength of a single dosage form submitted at the same time as the item above	$8,756	$9,893
		Documentation to support a change of manufacturer	$906	$1,025
	Supplement to a new drug submission (SNDS)	Efficacy data to support an additional indication in one animal species	$45,528	$51,445
		Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species	$35,006	$39,557
		Efficacy and safety data (in the intended species) to support an indication in another animal species	$57,787	$65,297
		Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration and dosage form and two indications in one animal species	$84,038	$94,961
		Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species	$113,795	$128,589
		Efficacy and safety data (in the intended species) to support the concurrent use of two drugs approved for the same animal species	$27,990	$31,628
		Comparative (pharmacodynamic, clinical or bioavailability) data to support an additional route of administration	$10,491	$11,855
		Comparative (pharmacodynamic, clinical or bioavailability) data to support each additional strength	$1,739	$1,964
		For food-producing animals, residue depletion studies to establish a new withdrawal period for a change in the dosage or route of administration of an approved dosage form in one species	$10,491	$11,855
		For food-producing animals, metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage and route of administration of an approved dosage form in an additional species	$52,506	$59,332
		For food-producing animals, toxicity studies to support a change of an established acceptable daily intake, a maximum residue limit and a withdrawal period	$26,254	$29,667
		For the concurrent use of two drugs in a species of food-producing animals, residue depletion studies to determine if an extension to existing withdrawal periods is required	$21,013	$23,744
		Chemistry and manufacturing data to support a change in the source of a medicinal ingredient or its manufacturing process	$17,505	$19,780
		Chemistry and manufacturing data to support a change in formulation or dosage form	$8,756	$9,893
		Chemistry and manufacturing data to support a change in the packaging or sterilization process	$6,982	$7,888
		Chemistry and manufacturing data to support an extension of the expiry date	$5,246	$5,930
		Chemistry and manufacturing data to support the concurrent use of two drugs	$5,246	$5,930
		Chemistry and manufacturing data to support a change in the manufacturing site for parenteral dosage form	$1,739	$1,964
		Documentation to support a change to the brand name of a drug	$906	$1,025
	Abbreviated new drug submission (ANDS) or supplement to an abbreviated new drug submission (SANDS)	Comparative (pharmacodynamic, clinical or bioavailability) data to support a single route of administration and dosage form	$10,491	$11,855
		For food-producing animals, residue depletion studies to confirm that the withdrawal periods for each species fall within the conditions of use for the Canadian reference product	$10,491	$11,855
		Chemistry and manufacturing data for a non-compendial medicinal ingredient of a drug	$17,505	$19,780
		Chemistry and manufacturing data to support a single dosage form	$17,505	$19,780
		Documentation to support (a) a change of manufacturer, in the case of an abbreviated new drug submission; or (b) a change to the brand name of a drug, in the case of a supplement to an abbreviated new drug submission	$906	$1,025
	Preclinical submission	Efficacy and safety data (in the intended species) and protocol to support the conduct of clinical studies relative to a single dosage form, route of administration and indication in one species	$17,505	$19,780
		Efficacy data and protocol to support the conduct of clinical studies relative to a single route of administration and indication with a dosage form for which a notice of compliance has been issued for use in the species to be treated	$13,997	$15,816
		For food-producing animals, toxicity, metabolism and residue depletion studies to establish a temporary acceptable daily intake, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species	$52,506	$59,332
		For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1 000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species	$78,793	$89,035
		For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1 000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species	$105,044	$118,700
		For food-producing animals (once an acceptable daily intake with a safety factor of 1 000 or less has been established), metabolism studies to establish a withdrawal period for a single dosage form, dosage and route of administration in an additional species	$26,254	$29,667
		Chemistry and manufacturing data to support a single dosage form containing a non-compendial medicinal ingredient	$17,505	$19,780
		Chemistry and manufacturing data to support a single dosage form containing a compendial medicinal ingredient	$8,756	$9,893
	Sale of new drug for emergency treatment	Information and material to support the sale of a new drug to be used in the emergency treatment of a non-food-producing animal	$62	$64
	Sale of new drug for emergency treatment	Information and material to support the sale of a new drug to be used in the emergency treatment of a food-producing animal	$124	$127
	Experimental studies certificate	Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a non-food-producing animal	$1,161	$1,181
		Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that of a previously authorized experimental studies certificate for a drug to be administered to a non-food-producing animal	$582	$592
		Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a food-producing animal	$3,498	$3,558
		Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that of a previously authorized experimental studies certificate for a drug to be administered to a food-producing animal	$582	$592
	Notifiable change or protocol review	Information and material to support an application for a notifiable change	$4,705	$5,316
	Notifiable change or protocol review	A protocol that is filed with the Minister and may support a new drug submission, an abbreviated new drug submission, a supplement to a new drug submission or abbreviated new drug submission, a preclinical submission or information and material that is filed for the purpose of obtaining an experimental studies certificate	$4,705	$5,316

Table 3: Fees for examination of an application for an establishment licence — drugs for human use (Schedule 3)
Section in the Fees in Respect of Drugs and Medical Devices Order	Activity	Fee as of April 1, 2025	Fee as of April 1, 2026
Sections 33 and 41	Fabrication — sterile dosage form	$49,558	$50,401
Sections 34 and 42	Importation	$38,265	$38,916
Sections 35 and 43	Fabrication — non-sterile dosage form	$36,740	$37,365
Sections 36 and 44	Distribution	$19,531	$19,864
Sections 37 and 45	Wholesaling	$11,398	$11,592
Sections 38 and 46	Packaging/labelling	$7,164	$7,286
Sections 39 and 47	Testing	$5,913	$6,014
Section 40	Foreign site (each)	$1,088	$1,107

Table 4: Fees for examination of an application for an establishment licence — drugs for veterinary use only (Schedule 4)
Section in the Fees in Respect of Drugs and Medical Devices Order	Activity	Fee as of April 1, 2025	Fee as of April 1, 2026
Sections 33 and 41	Fabrication — sterile dosage form	$49,215	$50,401
Sections 34 and 42	Importation	$38,265	$38,916
Sections 35 and 43	Fabrication — non-sterile dosage form	$31,671	$37,365
Sections 36 and 44	Distribution	$17,437	$19,864
Sections 37 and 45	Wholesaling	$6,973	$8,864
Sections 38 and 46	Packaging/labelling	$7,164	$7,286
Sections 39 and 47	Testing	$4,744	$6,014
Section 40	Foreign site (each)	$1,088	$1,107

Table 5: Fees for right to sell drugs for human use (Schedule 6)
Section in the Fees in Respect of Drugs and Medical Devices Order	Type of drug	Fee as of April 1, 2025	Fee as of April 1, 2026
Section 52	Disinfectant	$1,730	$1,760
	Non-prescription	$3,334	$3,391
	Drug other than one referred to in item 1 or 2 (above)	$5,531	$5,626

Table 6: Fees for right to sell drugs for veterinary use only (Schedule 7)
Section in the Fees in Respect of Drugs and Medical Devices Order	Type of drug	Fee as of April 1, 2025	Fee as of April 1, 2026
Section 56	Veterinary drug	$567	$577

Part 3 — Medical devices

Table 7: Fees for examination of an application for a medical device licence (Schedule 8)
Section in the Fees in Respect of Drugs and Medical Devices Order	Category	Fee as of April 1, 2025	Fee as of April 1, 2026
Section 60	Applications for Class II licence	$632	$643
	Applications for Class II licence amendment	$325	$331
	Applications for Class III licence	$13,926	$14,163
	Applications for Class III licence (near patient)	$29,664	$30,169
	Applications for Class III licence amendment — changes in manufacturing	$4,395	$4,470
	Applications for Class III licence amendment — significant changes not related to manufacturing	$11,178	$11,369
	Applications for Class IV licence	$30,199	$30,713
	Applications for Class IV licence amendment — changes in manufacturing	$4,395	$4,470
	Applications for Class IV licence amendment — significant changes not related to manufacturing	$15,979	$16,251
	Applications for Class II, III or Class IV licence or licence amendment — private label medical device	$176	$179

Table 8: Fees for examination of an application for an establishment licence — medical devices
Section in the Fees in Respect of Drugs and Medical Devices Order	Fee category	Fee as of April 1, 2025	Fee as of April 1, 2026
Section 71	Medical device	$5,426	$5,519

Table 9: Fees for right to sell licensed Class II, III or IV medical devices
Section in the Fees in Respect of Drugs and Medical Devices Order	Fee category	Fee as of April 1, 2025	Fee as of April 1, 2026
Section 77	Medical device	$452	$460

Table 10: Fees for the examination of a biocide application (Schedule 2.1)
Section in the Fees in Respect of Drugs and Medical Devices Order	Fee category	Fees as of May 31, 2025	Fees as of April 1, 2026
Section 27	Biocide full review — novel biocide	$41,685	$42,394
	Biocide full review — tier I	$8,595	$8,742
	Biocide full review — tier II	$11,469	$11,664
	Biocide full review — tier III	$13,523	$13,753
	Biocide comparison — labelling only	$2,748	$2,795
	Biocide comparison — administrative application	$975	$992
	Biocide — use of foreign decisions	$3,100	$3,153
	Biocide monograph	$1,861	$1,893
	Biocide major change — monograph	$1,363	$1,387
	Biocide major change — quality and risks	$4,955	$5,040
	Biocide minor change	$1,363	$1,387

Table 11: Fees for the right to sell biocides
Section in the Fees in Respect of Drugs and Medical Devices Order	Type of drug	Fee as of May 31, 2025	Fee as of April 1, 2026
Section 58	Biocide	$1,535	$1,562

DEPARTMENT OF HEALTH

PATENT ACT

Notice of annual increase of fee pursuant to the Certificate of Supplementary Protection Regulations

Notice is hereby given, that in keeping with subsection 9(1) of the Certificate of Supplementary Protection Regulations, the fee will increase by the annual 2% amount, rounded up to the nearest dollar.

The current fee and the fee updated as of April 1, 2026, are listed below.

Any inquiries or comments about the updated fee can be directed to Rosslynn Miller-Lee, Director General, Business Facilitation and Modernization Directorate, Health Products and Food Branch, 613‑327‑0798 (telephone) or cro-brc@hc-sc.gc.ca (email).

Annual increase of fee pursuant to the Certificate of Supplementary Protection Regulations
Type of certificate	Subsection in Certificate of Supplementary Protection Regulations	Fee as of April 1, 2025	Fee as of April 1, 2026
Certificate of Supplementary Protection	9(1)	$10,564	$10,776

DEPARTMENT OF TRANSPORT

CANADA MARINE ACT

Hamilton-Oshawa Port Authority — Supplementary letters patent

WHEREAS the Governor in Council issued a Certificate of Amalgamation containing letters patent to amalgamate the Hamilton Port Authority and the Oshawa Port Authority and to continue as one port authority named the Hamilton-Oshawa Port Authority (“Authority”), effective June 18, 2019;

WHEREAS Schedule C of the letters patent sets out the real property, other than federal real property, held or occupied by the Authority;

WHEREAS, pursuant to subsection 46(2) of the Canada Marine Act (“Act”), the Authority wishes to dispose of real properties described below;

WHEREAS the board of directors of the Authority has requested that the Minister of Transport (“Minister”) issue supplementary letters patent to reflect the disposition of the real property;

AND WHEREAS the Minister is satisfied that the amendments to the letters patent are consistent with the Act,

NOW THEREFORE, pursuant to subsection 9(1) of the Act, the letters patent of the Authority are amended as follows:

Schedule C of the letters patent is amended by adding the following after the description of “Part 1 (Hamilton) 5.”:
- SAVE AND EXCEPT
- Part of PIN 17579-0086 (LT) Part of Pier 8 Water Lot, Hamilton, being Part of the Bed of Hamilton Harbour, in the City of Hamilton, designated as Parts 1, 2, and 3 on Plan 62R-22239, Subject to an Easement as in Instrument No. WE1241304, in the City of Hamilton.
These supplementary letters patent take effect on the date of registration, in the Hamilton Land Registry Office, of the deeds of sale evidencing the transfer of the real property.

ISSUED this 23rd day of November, 2025.

The Honourable Steven MacKinnon, P.C., M.P.
Minister of Transport

DEPARTMENT OF TRANSPORT

CANADA MARINE ACT

Hamilton-Oshawa Port Authority — Supplementary letters patent

WHEREAS Schedule C of the letters patent sets out the real property, other than federal real property, held or occupied by the Authority;

WHEREAS, pursuant to subsection 46(2.1) of the Canada Marine Act (“Act”), the Authority wishes to acquire real property described below;

WHEREAS the board of directors of the Authority has requested that the Minister of Transport (“Minister”) issue supplementary letters patent to set out the real property in Schedule C of the letters patent;

AND WHEREAS the Minister is satisfied that the amendments to the letters patent of the Authority are consistent with the Act,

NOW THEREFORE, pursuant to subsection 9(1) of the Act, the letters patent of the Authority are amended as follows:

Schedule C of the letters patent is amended by adding the following after the description of “Part 2 (Oshawa) 1.”:
- 2. PIN 16378-0032 (LT), Part of Lot 5, Broken Front Concession, Geographic Township of East Whitby, now in the City of Oshawa, Regional Municipality of Durham, designated as Part 2 on Plan 40R-32520, known municipally as 1221 Farewell Street in the City of Oshawa.
These supplementary letters patent take effect on the date of registration, in the Oshawa Land Registry Office, of the deed of sale evidencing the transfer of the real property to the Authority.

ISSUED this 23rd day of November, 2025.

The Honourable Steven MacKinnon, P.C., M.P.
Minister of Transport

INNOVATION, SCIENCE AND ECONOMIC DEVELOPMENT CANADA

RADIOCOMMUNICATION ACT

Notice No. SMSE-010-25 — Consultation on the Policy, Technical and Licensing Framework for the VHF Maritime Frequency Bands

Notice is hereby given that Innovation, Science and Economic Development Canada (ISED) has released the Consultation on the Policy, Technical and Licensing Framework for the VHF Maritime Frequency Bands.

This consultation addresses the spectrum policy, licensing and technical considerations for maritime use in the frequency bands 156.000-157.450 MHz, 160.600-160.850 MHz and 161.575-162.050 MHz (referred to as VHF maritime mobile band). The primary intent of the consultation is to enable the implementation of the VHF Data Exchange System (VDES) in the bands 157.1875-157.3375 MHz and 161.7875-161.9375 MHz (referred to as VHF Data Exchange [VDE] bands). The consultation also addresses considerations in relation to the use of the VDE bands by maritime and non-maritime users, with a particular focus on areas where maritime services are given priority of use in accordance with international regulations in effect for the VHF maritime mobile band.

Building on these considerations, the consultation includes decisions regarding a displacement and licensing moratorium of analog maritime systems in the VDE bands, while seeking stakeholder input on proposed changes to the VHF maritime mobile band for the implementation of VDES in Canada (covering both the VDES terrestrial and satellite components). It also invites feedback on the future need for public correspondence duplex channels and potential revisions to RBR-2 — Technical Requirements for the Operation of Mobile Stations in the Maritime Service to enhance maritime channel availability within the band.

Interested parties should submit their comments no later than January 22, 2026. Reply comments should be submitted no later than February 23, 2026.

All comments and reply comments received in response to the consultation will be made available on ISED’s Spectrum management and telecommunications website.

Submitting comments

Respondents are requested to provide their comments in electronic format (Microsoft Word or Adobe PDF) to the following email: consultationradiostandards-consultationnormesradio@ised-isde.gc.ca.

Paper submissions should be mailed to the following address:

Senior Director
Terrestrial Engineering and Standards
Engineering, Planning and Standards Branch
Innovation, Science and Economic Development Canada
235 Queen Street, East Tower, 6th Floor
Ottawa, Ontario
K1A 0H5

All submissions should cite the Canada Gazette, Part I, the publication date, the title, and the notice reference number (SMSE-010-25).

Obtaining copies

Copies of this notice and of documents referred to herein are available electronically on ISED’s Spectrum Management and Telecommunications website.

Official versions of notices can be viewed on the Canada Gazette website.

November 21, 2025

Wen Kwan
Director General
Engineering, Planning and Standards Branch

INNOVATION, SCIENCE AND ECONOMIC DEVELOPMENT CANADA

RADIOCOMMUNICATION ACT

Notice No. SMSE-012-25 — Publication of BPR-10, issue 3

Notice is hereby given that Innovation, Science and Economic Development Canada has published the following document:

Broadcasting Procedures and Rules BPR-10, issue 3, Application Procedures and Rules for Digital Television (DTV) Broadcasting Undertakings, which outlines the application procedures for broadcasting undertakings seeking to acquire a broadcasting certificate to operate a digital television station, regular or low power.

This document is now official and available on the Published documents page of the Spectrum management and telecommunications website.

Submitting comments

Comments and suggestions for improving this document may be submitted online using the Standard Change Request form.

November 20, 2025

Wen Kwan
Director General
Engineering, Planning and Standards Branch

Marc-André Rochon
Director General
Spectrum Management Operations Branch

PRIVY COUNCIL OFFICE

Appointment opportunities

We know that our country is stronger — and our government more effective — when decision-makers reflect Canada’s diversity. The Government of Canada has implemented an appointment process that is transparent and merit-based, strives for gender parity, and ensures that Indigenous peoples and minority groups are properly represented in positions of leadership. We continue to search for Canadians who reflect the values that we all embrace: inclusion, honesty, fiscal prudence, and generosity of spirit. Together, we will build a government as diverse as Canada.

We are equally committed to providing a healthy workplace that supports one’s dignity, self-esteem and the ability to work to one’s full potential. With this in mind, all appointees will be expected to take steps to promote and maintain a healthy, respectful and harassment-free work environment.

The Government of Canada is currently seeking applications from diverse and talented Canadians from across the country who are interested in the following positions.

Current opportunities

The following opportunities for appointments to Governor in Council positions are currently open for applications. Every opportunity is open for a minimum of two weeks from the date of posting on the Governor in Council appointments website.

Governor in Council appointment opportunities
Position	Organization	Closing date
Parliamentary Budget Officer	Office of the Parliamentary Budget Officer